<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00757835</url>
  </required_header>
  <id_info>
    <org_study_id>A6219</org_study_id>
    <nct_id>NCT00757835</nct_id>
  </id_info>
  <brief_title>24-hr IOP With Travoprost/Timolol Compared With Latanoprost/Timolol in XFG</brief_title>
  <official_title>24-hour IOP Control With the Travoprost/Timolol Fixed Combination Compared With the Latanoprost/Timolol Fixed Combination, When Both Are Dosed in the Evening in Patients With Exfoliative Glaucoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aristotle University Of Thessaloniki</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Aristotle University Of Thessaloniki</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A crossover, randomized, single-masked study which compares the short-term (3 months) 24-hour
      IOP control and safety of travoprost/timolol fixed combination given once in the evening,
      versus that of latanoprost/timolol fixed combination given once in the evening in patients
      with exfoliative glaucoma. The primary objective of this trial is to compare the quality of
      24-hour IOP control after 3 months of chronic therapy with these two medications.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2008</start_date>
  <completion_date type="Actual">March 2009</completion_date>
  <primary_completion_date type="Actual">March 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Travoprost/timolol fixed combination will demonstrate better quality of 24-hour IOP control than latanoprost/timolol</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of side effects with the two medications</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Glaucoma</condition>
  <arm_group>
    <arm_group_label>Travoprost/timolol therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>treatment with travoprost/timolol fixed combination drops once in the evening for 3 months. 24-hour pressure monitoring.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Latanoprost/timolol therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment with latanoprost/timolol fixed combination for 3 months. 24-hour pressure monitoring.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>treatment with latanoprost/timolol fixed combination</intervention_name>
    <description>dosing in the evening with the two fixed combinations</description>
    <arm_group_label>Travoprost/timolol therapy</arm_group_label>
    <arm_group_label>Latanoprost/timolol therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>latanoprost/timolol fixed combination drops</intervention_name>
    <description>once in the evening</description>
    <arm_group_label>Travoprost/timolol therapy</arm_group_label>
    <arm_group_label>Latanoprost/timolol therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient has XFG and is older than 29 years

          -  The IOP without treatment is greater than 25 mm Hg and lower than 40 mm Hg at baseline
             (2 readings at 10:00)

          -  Patient can be safely washed out without risk for significant deterioration

          -  Distance best corrected Snelen visual acuity better than 0.1

          -  No contraindication to prostaglandins or Î²-blockers

          -  No history of lack of response (&lt;10% reduction) to any medication

          -  Patient can understand the instructions and comply to medications

          -  Open normal appearing angles

          -  No sign of ocular infection, except blepharitis, corneal abnormality that may affect
             IOP measurements etc

        Exclusion Criteria:

          -  History of trauma, inflammation, surgery, past use of steroids (within 2 months),
             severe dry eyes and use of contact lenses

          -  Patient is a female of childbearing potential or lactating mother
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anastasios G Konstas, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Glaucoma Unit, 1st University Department of Ophthalmology</affiliation>
  </overall_official>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 19, 2008</study_first_submitted>
  <study_first_submitted_qc>September 22, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 23, 2008</study_first_posted>
  <last_update_submitted>May 9, 2014</last_update_submitted>
  <last_update_submitted_qc>May 9, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Aristotle University Of Thessaloniki</investigator_affiliation>
    <investigator_full_name>AGP Konstas</investigator_full_name>
    <investigator_title>Professor in Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>24-hour IOP</keyword>
  <keyword>exfoliative glaucoma</keyword>
  <keyword>travoprost/timolol</keyword>
  <keyword>latanoprost/timolol</keyword>
  <keyword>fixed combinations</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glaucoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Timolol</mesh_term>
    <mesh_term>Latanoprost</mesh_term>
    <mesh_term>Travoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

